심혈관 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 적응증별, 의료 환경별, 지역별, 부문별 예측(2025-2033년)

Cardiovascular Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Indication, By Care Setting, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,656,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,111,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,021,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

심혈관 치료 시장 요약

세계의 심혈관 치료 시장 규모는 2024년에 2,411억 8,000만 달러로 추정되며, 2033년까지 3,831억 1,000만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 5.1%의 CAGR을 기록할 것으로 예상됩니다. 이러한 시장 성장은 좌식 생활습관, 부적절한 식습관, 비만, 그리고 전 세계 고령화에 따른 관상동맥질환, 뇌졸중, 심부전, 고혈압과 같은 심혈관질환(CVD)의 유병률 증가에 의해 주도되고 있습니다.

심장 건강 및 조기 진단에 대한 인식이 높아진 데다 영상 진단, 중재적 심장학, 최소침습 수술 기술의 발전으로 치료법의 보급이 가속화되고 있습니다. 또한, 약물 용출 스텐트, 생체흡수성 혈관 스캐폴드, 신규 항응고 요법 등의 기술 혁신으로 환자 치료 성적이 향상되고 임상 적용이 확대되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향 및 범위

• 시장의 역사
  • 상부 시장 분석
  • 관련 시장 분석
• 심혈관 치료 시장 - 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 툴 분석 : 심혈관 치료 시장
  • Porter's Five Forces 분석
  • PESTLE 분석

제4장 심혈관 치료 시장 : 치료 유형별 추정·동향 분석

• 심혈관 치료 시장 : 치료 유형별 : 주요 포인트
• 심혈관 치료 시장 : 치료 유형별 동향 및 시장 점유율 분석(2024년 및 2033년)
• 외과수술적 시술
  • 관상동맥 우회술 이식술(CABG)
  • 판막 수복/치환술
  • 심장 이식 수술
  • 기타
• 인터벤션 시술
  • 경피적 관상동맥 중재술(PCI)
  • 혈관성형술
  • 경카테터 대동맥판 치환술(TAVR)
  • 기타
• 비침습적 시술
  • 심장 재활
  • 물리치료 및 생활습관 개선
  • 기타

제5장 심혈관 치료 시장 : 적응증별 추정·동향 분석

• 심혈관 치료 시장 : 적응증별 : 주요 포인트
• 심혈관 치료 시장 : 적응증별 변동 분석 및 시장 점유율 분석(2024년 및 2033년)
• 허혈성 심질환(IHD)
• 심부전 및 심근증
• 부정맥 및 전도 장애
• 구조적 심질환 및 판막증
• 기타

제6장 심혈관 치료 시장 : 의료 환경별 추정·동향 분석

• 심혈관 치료 시장 : 의료 환경별 : 주요 포인트
• 심혈관 치료 시장 : 의료 환경별 변동 분석 및 시장 점유율 분석(2024년 및 2033년)
• 병원
• 외래 시설

제7장 심혈관 치료 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역별 시장 대시보드
• 세계 지역별 시장 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진입 기업별 최근 동향과 영향 분석
• 기업/경쟁 분류
• 주요 기업의 시장 포지션 분석, 2024년
• 기업 리스트
  • The Johns Hopkins Hospital
  • Cleveland Clinic
  • Icahn School of Medicine at Mount Sinai
  • Toronto General Hospital(University Health Network)
  • Sagar Hospitals
  • Sagar Hospitals
  • Medanta The Medicity
  • The University of Tokyo Hospital
  • Royal Papworth Hospital NHS Foundation Trust
  • London Bridge Hospital(HCA Healthcare UK)
  • Burjeel Hospital
  • King's College Hospital NHS Foundation Trust
  • Beneficente Israelita Brasileira Albert Einstein

KSM

영문 목차

영문목차

Cardiovascular Treatment Market Summary

The global cardiovascular treatment market size was estimated at USD 241.18 billion in 2024 and is projected to reach USD 383.11 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. This market growth is driven by the rising prevalence of cardiovascular diseases (CVDs) such as coronary artery disease, stroke, heart failure, and hypertension, fueled by sedentary lifestyles, poor dietary habits, obesity, and an aging global population.

Increasing awareness of heart health and early diagnosis, coupled with advancements in diagnostic imaging, interventional cardiology, and minimally invasive surgical techniques, accelerating treatment adoption. Moreover, technological innovations such as drug-eluting stents, bioresorbable vascular scaffolds, and novel anticoagulant therapies are enhancing patient outcomes and expanding clinical applications.

Global Cardiovascular Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiovascular treatment market report based on treatment type, indication, care setting, and region.

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Surgical Procedures
  • Coronary Artery Bypass Grafting (CABG)
  • Valve Repair/Replacement
  • Heart Transplant Surgery
  • Others
• Interventional Procedures
  • Percutaneous Coronary Intervention (PCI)
  • Angioplasty
  • Transcatheter Aortic Valve Replacement (TAVR)
  • Others
• Non-invasive Procedures
  • Cardiac Rehabilitation
  • Physical Therapy and Lifestyle Intervention
  • Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Ischemic Heart Disease (IHD)
• Heart Failure & Cardiomyopathies
• Cardiac Arrhythmias & Conduction Disorders
• Structural Heart & Valvular Disease
• Others
• Care Setting Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
  • 1.5.1. Commodity Flow Analysis
• 1.6. Data Validation & Publishing
• 1.7. List of Secondary Sources
• 1.8. Research Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segmental Snapshot
• 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. Cardiovascular Treatment Market- Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environmental Tools Analysis: Cardiovascular Treatment Market
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Cardiovascular Treatment Market: Treatment Type Estimates & Trend Analysis

• 4.1. Cardiovascular Treatment Market, By Treatment Type: Key Takeaways
• 4.2. Cardiovascular Treatment Market: Treatment Type Movement & Market Share Analysis, 2024 & 2033
• 4.3. Surgical Procedures
  • 4.3.1. Surgical Procedures Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Coronary Artery Bypass Grafting (CABG)
    • 4.3.2.1. Coronary Artery Bypass Grafting (CABG) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Valve Repair/Replacement
    • 4.3.3.1. Valve Repair/Replacement Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Heart Transplant Surgery
    • 4.3.4.1. Heart Transplant Surgery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.5. Others
    • 4.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Interventional Procedures
  • 4.4.1. Interventional Procedures Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Percutaneous Coronary Intervention (PCI)
    • 4.4.2.1. Percutaneous Coronary Intervention (PCI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Angioplasty
    • 4.4.3.1. Angioplasty Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Transcatheter Aortic Valve Replacement (TAVR)
    • 4.4.4.1. Transcatheter Aortic Valve Replacement (TAVR) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Non-invasive Procedures
  • 4.5.1. Non-invasive Procedures Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Cardiac Rehabilitation
    • 4.5.2.1. Cardiac Rehabilitation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Physical Therapy and Lifestyle Intervention
    • 4.5.3.1. Physical Therapy and Lifestyle Intervention Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cardiovascular Treatment Market: Indication Estimates & Trend Analysis

• 5.1. Cardiovascular Treatment Market, By Indication: Key Takeaways
• 5.2. Cardiovascular Treatment Market: Indication Movement & Market Share Analysis, 2024 & 2033
• 5.3. Ischemic Heart Disease (IHD)
  • 5.3.1. Ischemic Heart Disease (IHD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Heart Failure & Cardiomyopathies
  • 5.4.1. Heart Failure & Cardiomyopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cardiac Arrhythmias & Conduction Disorders
  • 5.5.1. Cardiac Arrhythmias & Conduction Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Structural Heart & Valvular Disease
  • 5.6.1. Structural Heart & Valvular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cardiovascular Treatment Market: Care Setting Estimates & Trend Analysis

• 6.1. Cardiovascular Treatment Market, By Care Setting: Key Takeaways
• 6.2. Cardiovascular Treatment Market: Care Setting Movement & Market Share Analysis, 2024 & 2033
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Outpatient Facilities
  • 6.4.1. Outpatient Facilities Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cardiovascular Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market position analysis, 2024
• 8.4. List of Companies
  • 8.4.1. The Johns Hopkins Hospital
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cleveland Clinic
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Icahn School of Medicine at Mount Sinai
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Toronto General Hospital (University Health Network)
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Sagar Hospitals
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Sagar Hospitals
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Medanta The Medicity
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. The University of Tokyo Hospital
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Royal Papworth Hospital NHS Foundation Trust
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Service benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. London Bridge Hospital (HCA Healthcare UK)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Service benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Burjeel Hospital
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Service benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. King's College Hospital NHS Foundation Trust
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Service benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Beneficente Israelita Brasileira Albert Einstein
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Service benchmarking
    • 8.4.13.4. Strategic initiatives

관련자료